Yes, chronic hepatitis B infection is one of the leading causes of liver cancer worldwide. It accounts for roughly 39% of all primary liver cancer cases globally, making it the single largest infectious cause. The lifetime risk for someone living with chronic hepatitis B is estimated at 27% for men and 8% for women, a striking difference from the general population.
How Hepatitis B Leads to Liver Cancer
Hepatitis B doesn’t cause cancer through a single mechanism. It works through several overlapping pathways, both direct and indirect, that can reinforce each other over time.
The virus inserts its own DNA into the genetic material of liver cells. This integration can physically disrupt genes that control cell growth, effectively flipping switches that shouldn’t be flipped. In many cases, the virus specifically targets a gene involved in maintaining telomeres, the protective caps on chromosomes that regulate how many times a cell can divide. When that gene is hijacked, cells gain the ability to replicate indefinitely, a hallmark of cancer.
Beyond this direct DNA damage, the virus produces two regulatory proteins that act like tumor promoters, encouraging the survival and growth of abnormal cells. Meanwhile, the immune system’s ongoing effort to fight the infection creates a cycle of chronic inflammation. Liver cells are constantly being destroyed and replaced, and each round of regeneration increases the chance of errors accumulating in the DNA. Over years or decades, these mutations pile up.
One particularly important detail: about 30% of hepatitis B-related liver cancers develop in people who don’t yet have cirrhosis. Most other causes of liver cancer, like alcohol-related liver disease, almost always require cirrhosis first. Hepatitis B can transform liver cells even without significant scarring, which means the cancer risk begins earlier than many people assume.
Viral Load and Cancer Risk
Not everyone with chronic hepatitis B faces the same level of risk. The amount of virus circulating in your blood, your viral load, is one of the strongest predictors. A large study published in JAMA tracked the relationship and found a clear dose-response pattern. Compared to people with very low viral levels (under 300 copies per milliliter), those with moderate levels were about 3 times more likely to develop liver cancer. At higher viral loads, the risk jumped to nearly 9 times greater. People with the highest levels, a million copies per milliliter or more, faced roughly 11 times the risk.
This gradient matters because it means suppressing the virus with treatment meaningfully changes your odds, and it also means that even without treatment, people with naturally low viral loads have a substantially lower risk than those with active viral replication.
Coinfection With Hepatitis D
About 5% of people with chronic hepatitis B are also infected with hepatitis D, a smaller virus that can only survive in the presence of hepatitis B. This coinfection is considered the most severe form of chronic viral hepatitis. It accelerates the progression to cirrhosis and liver cancer compared to hepatitis B alone. In people who acquire hepatitis D on top of an existing hepatitis B infection, 70 to 90% experience faster progression to serious liver disease. Hepatitis D coinfection may explain about 1 in 5 cases of liver disease and liver cancer among people living with hepatitis B. People who inject drugs, indigenous populations, and those with HIV or hepatitis C are at higher risk of carrying both viruses.
Antiviral Treatment Lowers the Risk
Long-term antiviral therapy doesn’t eliminate liver cancer risk entirely, but it reduces it significantly. In a Japanese study comparing treated and untreated patients, the five-year liver cancer rate dropped from 13.7% in untreated patients to 3.7% in those receiving antiviral treatment. A large Taiwanese study of patients who already had cirrhosis found that treatment cut the risk by about 60%. A six-year analysis of another antiviral found that treated patients developed liver cancer at roughly half the rate that risk models predicted they would without treatment.
The benefit is greatest for people who already have cirrhosis or high viral loads, the groups at highest baseline risk. For people with lower viral loads and no cirrhosis, the absolute risk reduction is smaller because the starting risk is lower, but treatment still helps by preventing disease progression.
Vaccination Has Already Prevented Thousands of Cancers
The hepatitis B vaccine, introduced in the 1980s, is effectively a cancer vaccine. The data from countries that adopted universal childhood vaccination early is remarkable. Taiwan launched its program in 1984, and liver cancer rates in children dropped by roughly 70% within the first two decades. In vaccinated age groups, the rate of liver cancer was about one-third that of unvaccinated groups across every age bracket studied. In one rural Chinese county, vaccination achieved 84% protective efficacy against liver cancer, with rates dropping from 1.41 per 100,000 in unvaccinated areas to 0.21 in vaccinated ones. In Alaska’s native population, where universal infant vaccination began in 1982 and achieved 93% coverage, liver cancer in children under 20 went from a peak incidence of 3 per 100,000 in the mid-1980s to zero by 1999.
Taiwan’s experience also shows the broader population effect. The prevalence of chronic hepatitis B infection fell from 9.8% at the start of the vaccination program to 1.3% within ten years. As vaccinated generations age into adulthood, liver cancer rates continue to decline in those cohorts.
Screening for Early Detection
Because the cancer risk persists even with treatment, people living with chronic hepatitis B need ongoing surveillance. The standard recommendation is an abdominal ultrasound combined with a blood test measuring a protein called AFP every six months. If the ultrasound shows a spot smaller than 1 centimeter, the typical approach is a follow-up ultrasound in three to six months, since very small spots are difficult to characterize accurately and most turn out to be benign. A new or growing spot 1 centimeter or larger, or a rising AFP level on consecutive tests, triggers more detailed imaging with a CT scan or MRI.
This semiannual screening schedule exists because liver tumors caught early, when they’re small and haven’t spread, are far more treatable. The screening applies to anyone at elevated risk, including men with hepatitis B over age 40, women over 50, anyone with cirrhosis regardless of age, and those with a family history of liver cancer.